Viterra plans new grain terminal in Saskatchewan

Sep 19, 2016

Terminal expected to be built in Wadena

By Diego Flammini
Assistant Editor, North American Content
Farms.com

Viterra recently announced plans to build a new grain terminal in Wadena, Saskatchewan.

The new terminal is expected to have a 34,000 metric tonne storage capacity and the ability to load up to 156 railcars through a loop track.

"We've worked closely with farmers in Wadena and surrounding areas for many years, and we're excited to be renewing our commitment to them through a new, world class grain facility that will meet their needs in today's competitive operating environment," said Kyle Jeworski, Viterra's President and CEO for North America, in a release. "By revitalizing our presence there, we will provide customers with convenient access to the superior service, marketing opportunities and advice that makes us an industry leader."

Viterra

Construction is scheduled to begin this fall, with the opening tentatively planned for fall 2018.

Recently, Saskatchewan has been the beneficiary of different agribusinesses building new facilities.

In June, GrainsConnect Canada announced it is building two new grain terminals in the province including one in Maymont. It could be running within the next two years.

In the same month, G3 Canada officially opened a high efficiency grain terminal in Pasqua, SK after construction began in 2014.

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.